Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by First Trust Advisors LP

First Trust Advisors LP raised its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 508.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 133,038 shares of the company's stock after acquiring an additional 111,163 shares during the period. First Trust Advisors LP's holdings in Elanco Animal Health were worth $1,611,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in ELAN. Wilmington Savings Fund Society FSB acquired a new stake in Elanco Animal Health in the third quarter worth about $35,000. Jones Financial Companies Lllp lifted its stake in shares of Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after acquiring an additional 2,059 shares during the period. SRS Capital Advisors Inc. boosted its holdings in shares of Elanco Animal Health by 221.2% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after acquiring an additional 3,411 shares in the last quarter. MRP Capital Investments LLC acquired a new position in shares of Elanco Animal Health during the fourth quarter valued at approximately $61,000. Finally, Blue Trust Inc. raised its holdings in Elanco Animal Health by 47.7% during the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after purchasing an additional 1,894 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Price Performance

Shares of ELAN opened at $9.53 on Wednesday. The business's 50-day moving average is $9.83 and its 200-day moving average is $11.43. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company has a market capitalization of $4.73 billion, a price-to-earnings ratio of 23.83, a P/E/G ratio of 2.50 and a beta of 1.49. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter in the previous year, the company earned $0.08 EPS. The firm's quarterly revenue was down 1.4% compared to the same quarter last year. Equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock in a transaction on Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the purchase, the director now directly owns 111,459 shares of the company's stock, valued at $1,136,881.80. The trade was a 9.86 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.89% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ELAN. UBS Group cut their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Piper Sandler reduced their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Stifel Nicolaus dropped their target price on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Barclays reduced their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Finally, Morgan Stanley dropped their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Elanco Animal Health has an average rating of "Hold" and a consensus price target of $14.67.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.